title: Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn).
abstract: The neuroprotective drug riluzole (Rilutek) is a sodium channel blocker and anti-excitotoxic drug which is marketed for the treatment of amyotrophic lateral sclerosis (ALS). Previous studies have shown that riluzole prolongs survival of transgenic mice harboring the mutated form of Cu,Zn-superoxide dismutase found in familial forms of the human disease. In this study we have examined the effect of treatment with riluzole in mice suffering from progressive motor neuronopathy (pmn), a hereditary autosomal recessive wasting disease which shares some symptoms of ALS. These mutants display hind limb weakness starting during the 3rd week of life and leading to paralysis and death during the 7th week of life. Daily treatment with 8 mg/kg of riluzole by oral route significantly retarded the appearance of paralysis, increased life span and improved motor performance on grip test and electromyographic results in the early stage of the disease. There was no effect of riluzole on weight gain. These data demonstrate that riluzole significantly prolongs life span, retards the onset of paralysis and slows the evolution of functional parameters connected with muscle strength in the pmn mouse model of motor neuron disease.
authors.affiliation: Neurodegenerative Disease Group, Aventis Pharma S.A., BP 14, 94403 Vitry-sur-Seine, France. philippe.kennel@aventis.com
authors.forename: P
authors.initials: P
authors.lastname: Kennel
authors.forename: F
authors.initials: F
authors.lastname: Revah
authors.forename: G A
authors.initials: GA
authors.lastname: Bohme
authors.forename: R
authors.initials: R
authors.lastname: Bejuit
authors.forename: P
authors.initials: P
authors.lastname: Gallix
authors.forename: J M
authors.initials: JM
authors.lastname: Stutzmann
authors.forename: A
authors.initials: A
authors.lastname: Imperato
authors.forename: J
authors.initials: J
authors.lastname: Pratt
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004195:Disease Models, Animal; D018737:Hand Strength / Q000502:physiology; D051379:Mice; D008822:Mice, Transgenic / Q000235:genetics; D016472:Motor Neuron Disease / Q000188:drug therapy* / Q000503:physiopathology; D018908:Muscle Weakness / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control*; D018482:Muscle, Skeletal / Q000187:drug effects / Q000503:physiopathology; D019782:Riluzole / Q000494:pharmacology*; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D019782:Riluzole